Mitoxantrone (CAS 65271-80-9) Antineoplastic Pharmaceutical API

Mitoxantrone (CAS 65271-80-9) is a potent anthraquinone antineoplastic API, renowned for its broad-spectrum anticancer activity against both solid tumors and hematological malignancies. Its unique molecular structure intercalates into DNA strands, inhibiting topoisomerase II activity to block cancer cell replication and induce apoptosis. This high-purity pharmaceutical raw material complies with strict international pharmacopoeial standards, ensuring consistent potency and stability for clinical formulation.

Widely utilized in oncology drug development, it serves as a core ingredient for medications treating breast cancer, leukemia, lymphoma, and prostate cancer. Valued for its favorable safety profile compared to traditional chemotherapeutic agents and its ability to synergize with other anticancer drugs, it addresses critical unmet needs for cancer treatment. Choose this trusted antineoplastic API to develop high-quality formulations that improve therapeutic outcomes for cancer patients.